ArQule, Inc. and Novartis Institutes for BioMedical Research, Inc. Initiate Chemistry Collaboration
ArQule, Inc., a drug discovery and development company, today announced that it has entered into a chemistry collaboration with Novartis Institutes for BioMedical Research, Inc. (NIBRI), an affiliate of Novartis AG. As part of this collaboration, ArQule will apply its integrated chemistry technology platform to generate and optimize small-molecule compounds for NIBRI's anti-infective drug discovery program. The terms of the agreement were not disclosed.
"The addition of Novartis, one of the world's leading R&D organizations, to our list of partners is further validation of our chemistry technologies business," said Dr. Stephen A. Hill, ArQule's President and Chief Executive Officer. "This announcement confirms our ability to add new customers for our chemistry services while continuing to build our internal proprietary portfolio of discovery and development programs."
Other news from the department science

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.